drugset
drugset / Trial / NCT01055847

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

NCT01055847 ↗

Phase 2 Completed 105 enrolled Gilead Sciences Salus Pharma, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.

Timeline

Start
2003-06
Primary completion
2004-08
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aztreonam Small molecule 75 mg Inhaled
Subject Aztreonam Small molecule 225 mg Inhaled

Indications

Pseudomonas aeruginosa infectious disease cystic fibrosis respiratory tract infectious disorder